Abstract：Objective To investigate the clinical effect of Trimetazidine combined with Metoprolol Succinate in the treatment of coronary heart disease (CHD)with heart failure.Methods A total of 100 CHD patients with heart failure treated in our hospital from February 2015 to March 2017 were selected,they were divided into the experimental group(n=50)and the control group (n=50)according to block randomization method.The control group received Metoprolol Succinate on the basis of basic treatment,while the experimental group received Trimetazidine and Succinate on the basis of basic treatment.The therapeutic effects,blood pressure,heart rate (HR),left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),plasma brain natriuretic peptide (BNP)and the incidence rate of adverse reactions were compared between the two groups.Results The total effective rate(96.00%)in the experimental group was higher than that in the control group(82.00%),and the difference was statistically significant(P＜0.05).The blood pressure,heart rate,LVESD and LVEDD levels in the experimental group were lower than those in the control group,and the levels of LVEF and BNP in plasma in the experimental group were higher than those in the control group,and the differences were statistically significant(P＜0.05).The total incidence of adverse reactions in the experimental group (8.00%)was lower than that in the control group(40.00%),the difference was statistically significant(P＜0.05).Conclusion Trimetazidine combined with Metoprolol Succinate can improve the therapeutic effect and cardiac function of CHD patients with heart failure,and it is safe to use Trimetazidine and Metoprolol Succinate.
京公网安备 11010502046607号